2021
Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers
MacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.Peer-Reviewed Original ResearchConceptsDose of nicotineNicotine reinforcementHigh doseSubjective effectsHuman laboratory studiesYoung adult smokersNicotine self-administration modelNon-dependent smokersOvernight nicotine abstinenceEffects modelSelf-administration modelSelf-administration procedureNicotine doseAdult smokersMethodsYoung adultsObjectivesThe current studyNicotine abstinenceNicotine addictionHigh dosesLow dosesPlaceboThreshold doseReinforcement thresholdTobacco productsDose
2018
E-cigarettes: Impact of E-liquid Components and Device Characteristics on Nicotine Exposure
DeVito EE, Krishnan-Sarin S. E-cigarettes: Impact of E-liquid Components and Device Characteristics on Nicotine Exposure. Current Neuropharmacology 2018, 16: 438-459. PMID: 29046158, PMCID: PMC6018193, DOI: 10.2174/1570159x15666171016164430.Peer-Reviewed Original ResearchConceptsNicotine exposureE-cigarettesNicotine dependenceEffective smoking cessation toolPrimary addictive componentSmoking cessation toolElectronic cigarette useE-liquidsAddictive componentCessation toolNicotine absorptionNicotine useCigarette usePuff topographyNicotine yieldE-liquid constituentsExposureCigarettesE-cigarette use behaviorsCurrent knowledgeUse behaviorsUnderstanding factorsSmokersFactorsCommon factors
2015
A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans
Jensen KP, DeVito EE, Herman AI, Valentine GW, Gelernter J, Sofuoglu M. A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. Neuropsychopharmacology 2015, 40: 2813-2821. PMID: 25948103, PMCID: PMC4864657, DOI: 10.1038/npp.2015.131.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCognition DisordersCotinineFemaleGenome-Wide Association StudyHeart RateHumansMaleMiddle AgedNerve Tissue ProteinsNeuropsychological TestsNicotineNicotinic AgonistsPolymorphism, Single NucleotideReceptors, NicotinicSmokingSubstance Withdrawal SyndromeSurveys and QuestionnairesConceptsAversive effectsHeavy smokingRisk allelesSmoking-related disordersAfrican American smokersCHRNA5-CHRNA3Doses of nicotineHigh nicotine doseNicotine administrationIntravenous doseNicotine effectsNicotine doseAmerican smokersWithdrawal severityOvernight abstinenceAcute responseAA subjectsCardiovascular reactivityCHRNB4 gene clusterNicotineEuropean AmericansAversive responsesAdministration sessionsSmokingCognitive performance
2013
Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase
DeVito EE, Herman AI, Waters AJ, Valentine GW, Sofuoglu M. Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase. Neuropsychopharmacology 2013, 39: 1431-1440. PMID: 24345818, PMCID: PMC3988546, DOI: 10.1038/npp.2013.339.Peer-Reviewed Original ResearchConceptsSubjective drug effectsMenstrual cycle phaseDrug effectsNicotine dependenceMenstrual cycle phase effectsFollicular phase womenSerious public health concernCycle phase effectsSymptoms of withdrawalLuteal phase femalesPublic health concernMenstrual phase differencesNicotine administrationOptimal treatmentIntravenous nicotineLuteal phaseOvernight abstinenceSmoking behaviorCycle phaseNicotine responseGreater physiological responsesBiochemical confirmationHealth concernEffects of sexBetter cognition